SUN-505 “Biochemical Storm In Silence: An Incidentally Discovered Pheochromocytoma With Life-threatening Potential”

Abstract Disclosure: A. Farid: None. D. Carrizo: None. Introduction: Pheochromocytomas are rare catecholamine-secreting tumors of the adrenal medulla that may remain clinically silent despite excessive hormonal activity. Although classic symptoms include paroxysmal hypertension, palpitations, diaphoresis, and headaches, many cases—especially those incidentally discovered—present without overt signs. However, unrecognized tumors can precipitate life-threatening complications such as hypertensive crises, arrhythmias, myocardial infarction, or stroke due to excessive circulating catecholamines¹. Clinical Case: A 53-year-old male with no history of hypertension, cardiac disease, or adrenergic symptoms underwent low-dose chest CT for lung cancer screening, which incidentally revealed a right adrenal mass. Dedicated adrenal protocol CT identified a 2.6 x 3.8 x 4.6 cm heterogeneously enhancing lesion with 58.9% absolute washout—indeterminate but concerning given size and imaging features.Endocrine workup showed normal aldosterone and cortisol. However, biochemical evaluation revealed markedly elevated plasma normetanephrine (916 pg/mL), total metanephrines (983 pg/mL), norepinephrine (2277 pg/mL), and dopamine (115 pg/mL), despite the patient being entirely asymptomatic. 24-hour urine collection further confirmed biochemical activity with normetanephrines 1724 mcg/24h (ref: 122-676), total metanephrines 1859 mcg/24h (ref: 224-832), and metanephrine 135 mcg/24h (ref: 90-315), over a urine volume of 2815 mL confirming the diagnosis of a biochemically active pheochromocytoma.The patient was pre-treated with titrated alpha-blockade using doxazosin, followed by beta-blockade, and underwent successful laparoscopic adrenalectomy. Pathology confirmed pheochromocytoma with focal capsular invasion but no malignant features. Postoperatively, catecholamines normalized and antihypertensives were discontinued. Conclusion: This case highlights the deceptive nature of biochemically active yet asymptomatic pheochromocytomas. Left undetected, such tumors pose a silent but serious risk for sudden cardiovascular events. Routine biochemical screening of adrenal incidentalomas remains crucial. Lifelong follow-up is warranted due to potential recurrence and genetic implications². References: 1. Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. 2. Bausch B, Wellner U, Bausch D, et al. Long-term prognosis of patients with pheochromocytoma: focus on clinical follow-up, risk of recurrence, and management of genetic predisposition. J Clin Endocrinol Metab. 2014;99(1):35-43. Presentation: Sunday, July 13, 2025

Authors

Institutions

Publication Details

Journal
Journal of the Endocrine Society
Published
2025-10-01
DOI
https://doi.org/10.1210/jendso/bvaf149.469
Primary Topic
Adrenal and Paraganglionic Tumors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SUN-505 “Biochemical Storm In Silence: An Incidentally Discovered Pheochromocytoma With Life-threatening Potential”

A. Farid, Debora Carrizo
Journal of the Endocrine Society
Adrenal and Paraganglionic Tumors
article

SUN-505 “Biochemical Storm In Silence: An Incidentally Discovered Pheochromocytoma With Life-threatening Potential”

A. Farid, Debora Carrizo
article en

Abstract

Abstract Disclosure: A. Farid: None. D. Carrizo: None. Introduction: Pheochromocytomas are rare catecholamine-secreting tumors of the adrenal medulla that may remain clinically silent despite excessive hormonal activity. Although classic symptoms include paroxysmal hypertension, palpitations, diaphoresis, and headaches, many cases—especially those incidentally discovered—present without overt signs. However, unrecognized tumors can precipitate life-threatening complications such as hypertensive crises, arrhythmias, myocardial infarction, or stroke due to excessive circulating catecholamines¹. Clinical Case: A 53-year-old male with no history of hypertension, cardiac disease, or adrenergic symptoms underwent low-dose chest CT for lung cancer screening, which incidentally revealed a right adrenal mass. Dedicated adrenal protocol CT identified a 2.6 x 3.8 x 4.6 cm heterogeneously enhancing lesion with 58.9% absolute washout—indeterminate but concerning given size and imaging features.Endocrine workup showed normal aldosterone and cortisol. However, biochemical evaluation revealed markedly elevated plasma normetanephrine (916 pg/mL), total metanephrines (983 pg/mL), norepinephrine (2277 pg/mL), and dopamine (115 pg/mL), despite the patient being entirely asymptomatic. 24-hour urine collection further confirmed biochemical activity with normetanephrines 1724 mcg/24h (ref: 122-676), total metanephrines 1859 mcg/24h (ref: 224-832), and metanephrine 135 mcg/24h (ref: 90-315), over a urine volume of 2815 mL confirming the diagnosis of a biochemically active pheochromocytoma.The patient was pre-treated with titrated alpha-blockade using doxazosin, followed by beta-blockade, and underwent successful laparoscopic adrenalectomy. Pathology confirmed pheochromocytoma with focal capsular invasion but no malignant features. Postoperatively, catecholamines normalized and antihypertensives were discontinued. Conclusion: This case highlights the deceptive nature of biochemically active yet asymptomatic pheochromocytomas. Left undetected, such tumors pose a silent but serious risk for sudden cardiovascular events. Routine biochemical screening of adrenal incidentalomas remains crucial. Lifelong follow-up is warranted due to potential recurrence and genetic implications². References: 1. Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. 2. Bausch B, Wellner U, Bausch D, et al. Long-term prognosis of patients with pheochromocytoma: focus on clinical follow-up, risk of recurrence, and management of genetic predisposition. J Clin Endocrinol Metab. 2014;99(1):35-43. Presentation: Sunday, July 13, 2025

Journal of the Endocrine SocietyVol. 9(Supplement_1)
Texas Tech University (US), Harrington Regional Medical Center (US), Amarillo VA Health Care System (US), Texas Tech University Health Sciences Center (US)
Openalex Percentile: Top 52%
Adrenal and Paraganglionic Tumors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.